Investigating Therapeutic Potential of Beta-Glucan on Experimental Toxoplasmosis in Immunocompetent and Immunocompromised Mice: In Silico and in Vivo Studies

Bibliographic Information
Authors: Aboul-Fotouh A.A.; Elfeky F.A.; Omar N.R.; Aboushousha T.; El-Wakil E.S.
Journal: Chemistry and Biodiversity
Publisher: John Wiley and Sons Inc
Publication Date: 22 April 2025
Volume / Issue: Volume 22 / Issue 8
Article No.: e202500370
ISSN: 16121872
Scopus: View on Scopus
PubMed: 40192266
Document Type: Article
Access: All Open Access; Bronze Open Access
Authors and Affiliations
Aboul-Fotouh A.A., Zoology Department, Faculty of Science for Girls, Al-Azhar University, Cairo, Egypt; Elfeky F.A., Zoology Department, Faculty of Science for Girls, Al-Azhar University, Cairo, Egypt; Omar N.R., Zoology Department, Faculty of Science for Girls, Al-Azhar University, Cairo, Egypt; Aboushousha T., Department of Pathology, Theodor Bilharz Research Institute, Giza, Egypt; El-Wakil E.S., Department of Parasitology, Theodor Bilharz Research Institute, Giza, Egypt
Abstract
There is a need to find efficient treatment for toxoplasmosis, a global disease with a public health concern, as the used therapeutics have limited effectiveness. Beta-glucan (β-glucan), a natural polysaccharide, has anti-inflammatory, immunomodulatory, and anti-infective activities against bacteria, viruses, and parasites. We aimed to investigate the therapeutic efficacy of β-glucan on toxoplasmosis using an in silico study and an in vivo mice model. The β-glucan drug-likeness characteristics were evaluated by molecular docking simulations, Lipinski's RO5 filter analysis, and the computational quantitative structural-activity relationships/absorption, distribution, metabolism, excretion, and toxicity predictive characteristics compared to spiramycin, an anti-toxoplasmosis drug. Sixty albino mice were divided into two divisions, immunocompetent and immunosuppressed. Each division contained five groups; healthy, diseased, spiramycin-treated, β-glucan-treated, and both β-glucan and spiramycin-treated groups. Parasitological, histopathological examinations, and immunological analysis were detected. β-glucan docked complexes demonstrated H-bonding and hydrophobic interactions towards their promising anti-toxoplasmosis targets compared to the spiramycin. The treated mice revealed a statistically significant reduction (p < 0.001) in the parasite burden. Regarding immunocompetent and immunosuppressed division, the group that was treated with both β-glucan and spiramycin, demonstrated the greatest outcomes, with 71% and 66% efficacy, respectively. It is concluded that β-glucan shows promising potential as an anti-toxoplasmosis candidate by potentiating the spiramycin effect and modulating the immunological response. © 2025 Wiley-VHCA AG, Zurich, Switzerland.
Keywords
antiprotozoal agents; drug discovery; T. gondii putative ribose-5-phosphate isomerase; toxoplasmosis; β-glucans; Animals; beta-Glucans; Disease Models, Animal; Female; Immunocompetence; Immunocompromised Host; Mice; Molecular Docking Simulation; Structure-Activity Relationship; Toxoplasma; beta glucan; spiramycin; antiprotozoal agent; animal experiment; animal model; Article; computer model; controlled study; drug absorption; drug distribution; drug excretion; drug metabolism; experimental toxoplasmosis; histopathology; immune response; in vivo study; male; molecular docking; mouse; mouse model; nonhuman; parasite load; parasitology; quantitative structure activity relation; toxicity; animal; chemistry; disease model; drug effect; drug therapy; immunocompromised patient; structure activity relation
Citation Information
Scopus Citations: 3
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
